awmsg logo



bortezomib (Velcade®)


Reference No. 65

Publication date:
19/08/2005


Appraisal information

bortezomib (Velcade®) 3.5 mg powder for solution for injection


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: 08/06/2005
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: Not available
Ministerial ratification: 19/08/2005

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA129) NICE GUIDANCE ISSUED OCTOBER 2007 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) The use of bortezomib (Velcade®) should be supported within NHS Wales in accordance with its licensed indications for the treatment of multiple myeloma for patients who have received two prior treatments and have demonstrated disease progression. Treatment must only be initiated and administered under the supervision of a physician qualified and experienced both in the use of chemotherapeutic agents and in the management of multiple myeloma.
Final Appraisal Recommendation (FAR)
Download